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Abstract
Background: Subgroup analyses in randomized trials examine whether effects of interventions
differ between subgroups of study populations according to characteristics of patients or
interventions. However, findings from subgroup analyses may be misleading, potentially resulting in
suboptimal clinical and health decision making. Few studies have investigated the reporting and
conduct of subgroup analyses and a number of important questions remain unanswered. The
objectives of this study are: 1) to describe the reporting of subgroup analyses and claims of
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subgroup effects in randomized controlled trials, 2) to assess study characteristics associated with
reporting of subgroup analyses and with claims of subgroup effects, and 3) to examine the analysis,
and interpretation of subgroup effects for each study's primary outcome.
Methods:  We will conduct a systematic review of 464 randomized controlled human trials
published in 2007 in the 118 Core Clinical Journals defined by the National Library of Medicine.
We will randomly select journal articles, stratified in a 1:1 ratio by higher impact versus lower
impact journals. According to 2007 ISI total citations, we consider the New England Journal of
Medicine, JAMA, Lancet, Annals of Internal Medicine, and BMJ as higher impact journals. Teams of two
reviewers will independently screen full texts of reports for eligibility, and abstract data, using
standardized, pilot-tested extraction forms. We will conduct univariable and multivariable logistic
regression analyses to examine the association of pre-specified study characteristics with reporting
of subgroup analyses and with claims of subgroup effects for the primary and any other outcomes.
Discussion: A clear understanding of subgroup analyses, as currently conducted and reported in
published randomized controlled trials, will reveal both strengths and weaknesses of this practice.
Our findings will contribute to a set of recommendations to optimize the conduct and reporting
of subgroup analyses, and claim and interpretation of subgroup effects in randomized trials.
Background
The effects of healthcare interventions on the entire study
population are of primary interest in clinical trials. It
remains appealing, however, for investigators and clini-
cians to identify differential effects in subgroups based on
characteristics of patients or interventions. This analytic
approach, termed subgroup analysis, can sometimes be
informative - but it is often misleading [1-4].
Investigators frequently conduct subgroup analyses
exploring multiple hypotheses [5]. Conducting multiple
tests is associated with the risk of false positive results due
to the play of chance [3]. This risk is particularly great if
subgroup analyses are data driven: that is, when investiga-
tors perform numerous post hoc subgroup analyses seeking
statistical significance. Even when investigators specify a
limited number of subgroup analyses a priori, the play of
chance may still result in identification of spurious sub-
group effects.
Sometimes, investigators explore possible subgroup
effects by testing the null hypothesis of no treatment effect
in each of the relevant subgroups. A claim of subgroup
effect is made if a significant effect is observed in one sub-
group but not in the other(s) [6,7]. This strategy, however,
fails to address the real issue of subgroup analysis: can
chance explain the apparent difference between sub-
groups? This question can be addressed with a formal test
of interaction in which the null hypothesis is that the
underlying effect across subgroups is the same. In another
instance, investigators report and claim the effect of one
subgroup of patients while ignore reporting of other sub-
groups. Investigators may also test the difference of effects
between groups according to the study characteristic
measured after randomization. The apparent difference of
effects may, however, be explained by the treatment inter-
vention itself, or by differing prognostic characteristics in
sub-groups that emerge after randomization, rather than
by the subgroup characteristic itself. Therefore, this
approach to analyzing subgroups is highly problematic
[4,8,9].
Many apparent subgroup effects have been proven to be
spurious [10]. Misleading subgroup effects can result in
withholding efficacious treatment from patients who
would benefit, or encourage ineffective or potentially
harmful treatments for subgroups who would fare better
without. It is, therefore, imperative to critically assess the
validity of claimed subgroup effects. One approach is to
use seven previously proposed criteria for determining
whether apparent differences in subgroup response are
likely to be real [11]. These criteria have been widely used
to evaluate subgroup analyses in randomized controlled
trials (RCTs) and meta-analyses [12-15]. Several new cri-
teria may further facilitate differentiation between spuri-
ous and real subgroup effects (Appendix 1).
A limited number of empirical studies have evaluated
how trialists conduct and report subgroup analyses, and
have revealed several weaknesses (Table 1) [16-21]. Weak-
nesses include the use of an excessive number of variables
and outcomes, inappropriate statistical methods, and
insufficient a priori specification of variables. A review of
subgroup analyses reported in cardiovascular trials [17],
for instance, identified one study reported 23 subgroup
variables and 17 outcomes. In another review of 27 surgi-
cal trials [16], a test of interaction was reported for only
5.8% (3/54) of subgroup hypotheses tested, whereas
72.2% (39/54) claimed subgroup effects. Across six
reviews of subgroup analyses, the prevalence of trialsTrials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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claiming at least one subgroup effect ranged from 25% to
60% [16-20]. Two studies - one [18] restricted to trials
published in the New England Journal of Medicine, and
another [17] restricted to moderate or large sized cardio-
vascular trials - found that larger sample size was the only
study characteristic statistically associated with reporting
of subgroup analyses.
Despite the merits of these studies, each of them exam-
ined only a relatively small number of trials (median 57,
range 11-97). None compared the reporting of subgroup
analyses in higher impact journals versus other journals;
none examined the reporting of subgroup analyses in rela-
tion to type of outcomes (e.g. continuous, binary, time-to-
event, count, or multinomial); and none specifically
examined subgroup analysis reporting for the primary
outcome. In addition, none of the previous reviews docu-
mented the magnitude of the apparent subgroup effects
and magnitude of p-values of interaction tests; none
investigated the validity of claimed subgroup effects; none
investigated study characteristics associated with claim of
subgroup effects; and none addressed the credibility of the
claimed subgroup effects.
These shortcomings limit the generalizability of findings
and leave important questions unanswered. Therefore, we
will conduct a systematic review of RCTs to further inform
the current use and reporting of subgroup analyses.
In this study, we have three main objectives. The first is to
describe the reporting of subgroup analyses and claim of
subgroup effects. The second is to assess study characteris-
tics associated with reporting of subgroup analyses, and
study characteristics associated with claim of subgroup
effects, both for the primary outcome and for any out-
come. The third objective is to examine the analysis and
interpretation of subgroup effects conducted for the pri-
mary outcome.
Methods
Study Design Overview
We will conduct a systematic review of RCTs conducted in
humans and published in 2007 in the Core Clinical Jour-
nals defined by the National Library of Medicine http://
www.nlm.nih.gov/bsd/aim.html. To maximize the gener-
alizability of study findings, we will include parallel,
cross-over, and factorial randomized trials, and both indi-
vidual and cluster randomised trials. Unless the authors
report findings to the contrary, we will assume no treat-
ment-by-treatment interaction in factorial studies, no
treatment-by-sequence interaction in cross-over studies,
and no treatment-by-cluster interactions in cluster-rand-
omized studies. We will use the standard methodology for
conducting systematic reviews [22].
Definition of Subgroup, Subgroup Analysis, and Subgroup 
Effect
For this study, we define a subgroup as a subset of a trial
population that is identified on the basis of a patient or
intervention characteristic that is either measured at base-
line or after randomization.
We define a subgroup analysis as a statistical analysis that
explores whether effects of the intervention (i.e. experi-
Table 1: Characteristics of six studies reviewing subgroup analyses in randomized trials
Study ID Trial area Source of study Number of trials Trial feature for eligibility 
criteria
Wang (2007) Multiple NEJM (July 2005 to June 2006) 97 
(59 reporting subgroup 
analyses)
No restrictions
Bhandari (2006) Surgical Two surgical journals plus NEJM, 
JAMA, BMJ, and Lancet 
(Jan 2000 to Apr 2003)
72 
(27 reporting subgroup 
analyses)
No restriction on size and other trial 
characteristics
Hernandez (2006) Cardiovascular Four cardiovascular journals plus 
"Top Five" (2002 and 2004)
63 
(39 reporting subgroup 
analyses)
Phase 3 parallel trials, n ≥ 100, 
superiority trials; restricted to main 
reports
Hernandez (2005) Traumatic brain MEDLINE (1966 to Apr 2004), 
EMBASE (1978 to Apr 2004), 
CENTRAL (Apr 2004)
18 
(11 reporting subgroup 
analyses)
Phase 3, parallel trials, n ≥ 50 per 
arm
Glasgow Outcome Scale (GOS) at 3 
months as outcome
Moreira Jr (2001) Multiple NEJM, JAMA, Lancet, American 
Journal of Public Health (July 1998)
32 
(17 reporting subgroup 
analyses)
No restrictions mentioned.
Assmann (2000) Multiple NEJM, JAMA, BMJ, and Lancet 
(July to Sep 1997)
50 
(35 reporting subgroup 
analyses)
No crossover and cluster trials, n ≥ 
50Trials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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mental versus control) differ according to status of a sub-
group variable. This includes a case in which investigators
report a main result and analyze only a subset of patients.
We define a subgroup effect as a difference in the magni-
tude of a treatment effect across subgroups of a study pop-
ulation. The null hypothesis for a test of a subgroup effect
(i.e. subgroup hypothesis) is that there is no difference in
the magnitude of a treatment effect across subgroups. We
will consider both absolute and relative effect measures in
our study.
Eligibility Criteria
The inclusion criteria are:
1) The study is an RCT;
2) The participants are human;
3) The study is published in 2007 in a core clinical journal
(as defined by the National Library of Medicine).
The exclusion criteria are:
1) The report does not include the entire population
enrolled in the original study (i.e. the report focuses on a
subset of the original study population);
2) The study is explicitly labelled as a phase I trial;
3) The study is exclusively a pharmacokinetic study;
4) The study is reported as a Research Letter.
No restrictions apply with respect to the following aspects:
￿ Trial design (i.e., parallel, factorial or cross-over);
￿ Number of trial arms (i.e., two or more);
￿ Unit of randomization (i.e., individual patient or clus-
ter);
￿ Type of outcome (i.e., continuous, binary, time-to-
event, count, or multinomial);
￿ Type of trial (i.e., superiority, non-inferiority or equiva-
lence trial);
￿ Type of report (i.e., main report, longer follow-up
report, or interim report);
￿ Subgroup variables measured at baseline versus after
randomization.
￿ Sample size, length of follow up, and loss to follow up;
￿ Statistical significance versus non-significance of overall
main effects;
Literature Search
We will search for RCTs published in the Core Clinical
Journals in 2007. This group of journals is defined by the
National Library of Medicine, includes a total of 118 jour-
nals covering all specialities of clinical medicine and pub-
lic health sciences, and is known as the Abridged Index
Medicus. We will run the Medline search using the OVID
platform and a search strategy (Appendix 2) developed
with the help of an experienced librarian.
Random Sampling of Citations
We will stratify the Core Clinical Journals into higher and
lower impact journals. For this study we define higher
impact journals as the five journals with the highest total
citations in 2007: the New England Journal of Medicine,
JAMA, Lancet, Annals of Internal Medicine, and BMJ. Lower
impact journals consist of the remaining Core Clinical
Journals. We will randomly sample the journal articles,
with 1:1 stratification by journal type (i.e. higher and
lower impact). We will continue the random sampling
process until the number of eligible studies meets our
required sample size.
Review process
Teams of two trained reviewers will perform citation and
full text screening and data abstraction, in duplicate and
independently, including the selection of the primary out-
come (using pre-specified criteria - see below), selection
of the pair-wise comparison for analysis (if there are three
or more arms). Each team will attempt to resolve discrep-
ancies by consensus or, if discrepancy remains, through
discussion with one of two arbitrators (XS, GHG). The
arbitrator will independently review the trial report before
discussing it with the reviewers. Before the review for-
mally starts, we will conduct calibration exercises to
ensure consistency across reviewers. We will use electronic
forms, developed with Microsoft Access and Excel, for
study screening and data extraction. The forms will be
standardized and pilot-tested, and detailed written
instructions will be developed to assist with study screen-
ing and data extraction.
Study Screening
Two reviewers will independently screen the title and
abstract of each randomly chosen citation for potential
eligibility. In the title and abstract screening, they will
judge only if the study is a randomized controlled trial
enrolling human participants. Two reviewers will then
independently screen the full text of the potentially eligi-
ble trials to determine eligibility.Trials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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At the full text screening stage, the reviewers will select a
primary outcome for eligible studies, using the following
strategy: If the report specifies a primary outcome, we will
select it as the primary outcome; if the report specifies
more than one primary outcome (i.e. co-primary out-
comes), we will select the one with the largest number of
subgroup analyses; if outcomes have the same number of
subgroup analyses, we will select the one with the greatest
relevance to patients according to a pre-defined outcome
hierarchy, and if more than one outcome are in the same
category, we will take the first reported outcome in the
abstract (Appendix 3). If the report does not specify a pri-
mary outcome, we will select the outcome used for the
study sample size calculation, but if there is no sample
size calculation reported or if there is a sample size calcu-
lation for several outcomes, we will proceed as detailed in
the previous sentence.
Reviewers will also identify a pair-wise comparison of
interest, using the following strategy. If there are only two
groups, we will use them for the pair-wise comparison. If
there are three or more groups, we will select the compar-
ison that was clearly and explicitly defined as the primary
comparison in the study report; if the primary comparison
was not explicitly defined, we will select the comparison
that reports the largest number of subgroup analyses for
the selected primary outcome; if more than one compari-
son reported the same largest number of subgroup analy-
ses, we will select the comparison that reports the smallest
interaction p value; if the interaction p value is not availa-
ble, we will select the one that has the smallest p value for
the main effect.
Data Abstraction
Study Characteristics
We will extract information on funding sources, clinical
area, type of intervention, trial design (parallel, cross-over,
or factorial), trial type (superiority, non-inferiority, or
equivalence), unit of randomization (randomization at
individual or cluster level), methodological characteristics
of trials (allocation concealment; blinding of patients,
healthcare givers, data collectors, outcome adjudicators,
or data analysts; stopping trials early for benefit), number
of participants randomized for the selected comparison,
and total number of participants randomized.
We will categorise the selected primary outcome, accord-
ing to whether it is a composite endpoint, whether the
results are statistically significant, and the type of outcome
variable (time-to-event, binary, continuous, count, or
multinomial). We will record the type of effect measure
for the selected primary outcome. If more than one effect
measure is used for binary, time-to-event, or count out-
comes, we will use a hierarchical approach to select an
effect measure, as follows:
￿ Select the effect measure that the investigators clearly
indicated as the effect measure for the primary analysis;
￿ Select the effect measure on which the subgroup analysis
is reported and a subgroup effect is claimed;
￿ Select the measure that yields the smallest reported p-
value of the main effect;
￿ Otherwise, use the following order for binary outcomes:
risk ratio > odds ratio > relative risk reduction > risk differ-
ence; and the following for time-to-event outcomes: haz-
ard ratio > incidence rate ratio > ratio of cumulative
incidence > ratio of time > difference in incidence rate >
difference in cumulative incidence > difference in time
If no effect measure is reported but data for a 2 × 2 table
are available for the primary outcome, we will calculate
risk ratios.
For binary, time-to-event, and count primary outcomes,
we will document their point estimates and 95% confi-
dence intervals for the main effects, as well as - whenever
possible - events and number of patients in a 2 × 2 table.
For continuous outcomes, we will document the number
of patients analyzed in the experimental and control
groups, and the summary measure (i.e. means, medians)
and associated measure of precision (i.e. inter-quartile
range, 95% confidence interval, standard deviation, or
standard error). We will not document the magnitude of
the main effect for multinomial primary outcomes.
Reporting of subgroup analyses
We will record whether trials report subgroup analyses for
any outcomes (i.e. primary or secondary), the number of
outcomes for which subgroup analyses are reported, the
type of outcomes, the number of subgroup variables
reported in the trial report, the number of subgroup anal-
yses that were most likely conducted, the number of sub-
group analyses reported, whether any subgroup analysis
was specified a priori, and whether any subgroup effect
was stated to have been analyzed by a test of interaction.
We will also document the above information specifically
for the primary outcome.
We will consider a subgroup analysis has been reported if:
1) the investigators report a point estimate and an associ-
ated confidence interval or a p-value for one or more sub-
groups of the study original population, 2) the
investigators report the magnitude of difference in the
effect according to status of a subgroup variable, 3) the
investigators report results from an interaction test, or 4)
the investigators explicitly state that they conducted sub-
group analyses but do not report any of the data men-
tioned above.Trials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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Claim of subgroup effects
We will record whether trials claim a subgroup effect for
any outcomes (i.e. primary or secondary outcome),
number of subgroup effects claimed in the trial report,
and type of outcomes used for the claim. We will judge the
strength of the claim based on the inferences drawn by the
investigators in the abstract or discussion section. We will
also document the above information specifically for the
primary outcome.
We will consider a subgroup effect is claimed if, in the
abstract or discussion of the trial report, the investigators
state that the effects of intervention differed, or may have
differed, according to status of a subgroup variable.
We will classify the strength of a claim according to four
categories, and have defined these categories as below:
1) Strong claim of a definitive effect: The authors convey
a conviction that the subgroup effect truly exists.
2) Claim of a likely effect: The authors convey a belief that
the subgroup effect likely exists.
3) Suggestion of a possible effect: The authors suggest a
subgroup effect and convey an uncertainty whether the
subgroup effect exists.
4) No claim of a subgroup effect: The authors do not make
a claim of a subgroup effect.
We have developed explicit criteria to judge the strength of
claim (Table 2).
Analysis of subgroup effect for the primary outcome
We will document, for each subgroup analysis, whether
the subgroup variable is a baseline characteristic or based
on an after-randomization event, whether the investiga-
tors specified the variable a priori, whether the investiga-
tors specified the direction a priori, whether the subgroup
variable was used as a stratification factor in randomiza-
tion, the type of tests used for analyzing subgroup effects
(test of significance of individual groups, interaction test,
or both), the statistical approaches used for a test of inter-
action, and the methods of adjusting for multiple interac-
tion effects.
We will also document, whenever possible, the 2 × 2 data,
the reported point estimate, 95% confidence interval, and
p-value of the effect of each subgroup, as well as the
reported p-value of the interaction test.
Interpretation of claimed subgroup effect for the primary outcome
For each of the claimed subgroup effects, we will further
document whether the authors provided a supportive bio-
logical rationale or cited external evidence that is consist-
ent with the observed subgroup effect, whether the
authors indicated that the pre-specified direction was cor-
rect, or that they indicated the observed subgroup effect
was consistent across closely related outcomes.
Table 2: Criteria for judging the strength of a subgroup claim
Criteria Strong claim Claim of a likely effect Suggestion of a possible effect
1. Did the investigators claim the effect in the abstract? Yes Possible No
2. Did the investigators claim the effect in the conclusion 
of abstract?
Possible* No No
3. Did the investigators claim the effect in the discussion? Yes Possible Yes
4. Did the investigators use the descriptive words (e.g. 
appear/seem to be, may, and might) to soften their 
statements of the claims?
No Possible Possible
5. Did the investigators used descriptive words (e.g. 
particular, and special) to strengthen the statement of the 
claims
Possible No No
6. Were the authors obviously cautious about the 
apparent subgroup effect? (e.g. they stated the subgroup 
effect did not meet some of important criteria to believe a 
subgroup effect)
No Some caution possible Yes
7. Did the investigators indicate the apparent effects need 
to be explored in the future studies (i.e. hypothesis 
generating)?
No Possible say desirable to confirm Yes
* If a claim appears in the conclusion section of the abstract, it is considered a strong claim.Trials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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Sample Size
We conducted a pilot study including 139 randomized tri-
als. The results showed that 62 (44.6%) trials reported
subgroup analyses for any outcome, and 41 (29.5%)
reported for the primary outcome; 27 (19.4%) trials
claimed subgroup effect for any outcome, and 18 (12.9%)
claimed for the primary outcome.
We calculate the sample size based on the examination of
study characteristics associated with claim of subgroup
effects for any outcome. In our regression of study charac-
teristics with claim of subgroup effects, we will include 6
study characteristics, a total of 9 categories of variables.
We will require 10 events (i.e. claim of subgroup effect)
per category to examine the association, resulting in a
total of 90 events (and at least 90 total non-events). Given
the results of pilot study, we will require a total of 464 tri-
als for this study.
Statistical Analysis
We will assess agreement between reviewers for study
inclusion at the full text screening stage, reviewers' judg-
ments whether the investigators reported a subgroup anal-
ysis, claimed a subgroup effect, pre-specified the subgroup
hypothesis, or used the interaction test. We will calculate
both crude agreement and chance-corrected agreement.
We will interpret the agreement statistics using the guide-
lines proposed by Landis and Koch [23]: kappa values of
0 to 0.20 represent slight agreement, 0.21 to 0.40 fair
agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80
substantial agreement, and greater than 0.80 almost per-
fect agreement.
We will calculate the proportions of trials reporting at
least one subgroup analysis for the primary outcome and
for any outcome. Treating the reporting of a subgroup
analysis as the dependent variable, we will conduct uni-
variable and multivariable logistic regression analyses to
examine its association with the pre-specified study char-
acteristics for both the primary outcome and for any out-
come.
We will also calculate the proportions of trials claiming a
subgroup effect for the primary outcome and for any out-
come in trials that report a subgroup analysis, and con-
duct univariable and multivariable logistic regression
analyses to examine the association of pre-specified study
characteristics with claim of a subgroup effect for the pri-
mary outcome and for any outcome.
Our pre-specified study characteristics for the regression
analyses are: average sample size per study arm, journal
type (high vs. lower impact journals), source of funding
(partially or completely funded by private for profit
organization vs. others), statistical significance of the
main effect, trial area (medical vs. surgical), number of
pre-specified primary outcomes (used for the regression of
reporting of subgroup analyses only), number of sub-
group analyses (used for the regression of claim of sub-
group effects only). We hypothesize that trials are more
likely to report subgroup analyses or claim subgroup
effect if they have larger sample size, are published in
higher impact journals, receive funding from for profit
organizations, do not achieve statistical significance for
the main effect, investigate medical versus surgical inter-
ventions, have more pre-specified primary outcomes, and
larger number of subgroup analyses. In the multiple logis-
tic regression analysis for reporting of subgroup analysis,
we will also examine the interaction of source of funding
and significance of main effect.
We will describe the details of reporting of subgroup anal-
yses and claim of subgroup effects for both any outcome
and specifically for the primary outcome. If a variable, in
both univariable and multivariable analyses, is found to
be significantly associated with reporting of a subgroup
analysis and/or claim of a subgroup effect, we will also
present the above information stratified by the type of
journal.
We will describe the details of analysis of subgroup effects
for the primary outcome by journal type (i.e. five highest
impact journals versus other journals), and by claim ver-
sus no claim of a subgroup effect. We will also describe the
details of interpretation of claimed subgroup effects by
journal type.
Discussion
Our study is designed to comprehensively address the
analysis, reporting, and claim of subgroup effects in a rep-
resentative sample of recent RCTs. This study protocol fol-
lows the publications of two other protocols [24,25]
which reflects our continuing efforts to make objectives
and design of methodological studies more transparent.
Strengths and limitations
Our study has several strengths. First, we will employ rig-
orous systematic review methods including explicit and
reproducible eligibility criteria, sensitive search strategies,
and the use of standardized, pilot-tested forms accompa-
nied by written instructions for study screening and data
extraction. Teams of two trained reviewers will independ-
ently and in duplicate conduct study screening. We will
also undertake calibration exercises and pilot data extrac-
tion to enhance consistency between reviewers before
embarking on data abstraction. Second, our eligibility cri-
teria are broad, and compared to the previous empirical
studies our study findings will be more generalizable.
Third, we conducted a pilot study to calculate the required
sample size for the definitive study. Finally, our study willTrials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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be the largest empirical study of subgroup analyses which
will allow us to reliably address a number of important
questions that have not been addressed by existing
reviews.
Our study also has several limitations. It will be based on
reported trial information, and our findings may be vul-
nerable to underreporting or selective reporting [26]. The
limited space allowed by medical journals for reporting
on trials may prevent authors from sufficiently reporting
relevant information on subgroup analyses. Conse-
quently, the proportion of trials reporting subgroup anal-
yses is probably smaller than the proportion of trials
actually conducting subgroup analyses, and the number
of subgroup analyses reported in each trial is probably
smaller than the actual number of conducted subgroup
analyses. In relation to this problem, we will also estimate
the number of subgroup analyses that were most likely
conducted. Similarly, other details about subgroup analy-
ses, such as a priori specification of the subgroup hypoth-
esis and direction, may also be under-reported.
Our study does not include all medical journals, and our
findings may not be applicable to journals outside our
sample. Our study, however, includes many more jour-
nals than the previous studies that typically included high
impact journals or specialty journals only. We chose the
Core Clinical Journals because they cover all clinical and
public health areas, and include all major medical jour-
nals. We consider that the quality of studies in these jour-
nals will be no worse than that in other journals, and
expect that the quality of subgroup analyses reported in
other journals will be no better than that in the Core Clin-
ical Journals.
Our study will involve reviewers' judgement of the
strength of the claim of subgroup effect, and the determi-
nation of strength may be subjective and vary across
reviewers. We have developed detailed written instruc-
tions to assist reviewers in judging the strength, and will
check the inter-reviewer agreement.
Implications of this study
Although a few empirical studies restricted to certain dis-
ease areas or journal type have found a significant associ-
ation between sample size and reporting of subgroup
analyses, factors that drive reporting and claiming of sub-
group effects in a more representative set of trials remain
uncertain. The results of this study will provide robust,
generalizable, and reliable evidence on the factors that
impact reporting and claiming of subgroup effects.
Considerable work, including methodological advocacy
[3,27-31] and empirical investigation [5,18,19], has been
done to inform the conduct of subgroup analyses. How-
ever, few reports have systematically developed the frame-
work of analysis, reporting, claim, and interpretation of
subgroup effects. The findings of this study will further aid
in the development of recommendations for adequate
reporting, and appropriate analysis, claim, and interpreta-
tion of subgroup effects.
Claimed subgroup effects are of primary interest to clini-
cians, investigators and other users. Claims of spurious
subgroup effects can distort clinical practice and public
health decision making, with serious consequences for
patients and unnecessary expenditures. Methodological
safeguards have been proposed to protect from spurious
subgroup findings [4,10,30], but empirical evidence of
their validity is limited. The results of this study will reveal
the extent to which the investigators considered method-
ological safeguards in their claims, and provide some evi-
dence regarding the extent to which claims of subgroup
effects are valid.
The findings of the SATIRE study may influence recom-
mendations on reporting, conduct, claim, and interpreta-
tion of subgroup analyses. These will be of particular
interest to the stakeholders that have direct influence on
trial design, analysis, and reporting, including investiga-
tors, health decision makers, guideline developers, fund-
ing agencies, and medical journal editors.
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Appendices
Appendix 1. The eleven criteria for assessing credibility of 
claimed subgroup effects
￿ Is the subgroup variable a characteristic at randomization?
￿ Is the effect suggested by comparisons within rather than
between studies?
￿ Does interaction test suggests a low likelihood that
chance explains the apparent subgroup effect?
￿  Is the significant interaction effect independent of other
potential subgroup effects?
￿ Was the hypothesis specified a priori?
￿ Was the correct direction of subgroup effect specified a priori?Trials 2009, 10:101 http://www.trialsjournal.com/content/10/1/101
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￿ Was the subgroup effect one of a small number of
hypothesized effects tested?
￿ Is the magnitude of the subgroup effect large?
￿ Is the interaction consistent across studies?
￿ Is the interaction consistent across closed related outcomes
within the study?
￿ Is there indirect evidence that supports the hypothesized
interaction?
The new criteria are italicized.
Appendix 2: Search strategy
1. exp Randomized Controlled Trials/
2. (randomized controlled trial$ or randomised control-
led trial$).mp. [mp = title, original title, abstract, name of
substance word, subject heading word]
3. (randomized trial$ or randomised trial$).mp. [mp =
title, original title, abstract, name of substance word, sub-
ject heading word]
4. (randomized clinical trial$ or randomised clinical
trial$).mp. [mp = title, original title, abstract, name of
substance word, subject heading word]
5. 1 or 2 or 3 or 4
6. limit 5 to (English language and humans and "core
clinical journals (aim)" and yr="2007")
Appendix 3: Hierarchy of outcomes
I. Mortality
1) all cause mortality
2) disease specific mortality
II. Morbidity
1) cardiovascular major morbid events
2) other major morbid events (e.g. loss of vision,
seizures, fracture, revascularization)
3) recurrence/relapse/remission of cancer/disease
free survival
4) renal failure requiring dialysis
5) hospitalizations
6) infections
7) dermatological/rheumatologic disorders
III. Symptoms/Quality of life/Functional status (e.g.
failure to become pregnant, successful nursing/breast-
feeding, depression)
IV. Surrogate outcomes (e.g. viral load, physical activ-
ity, post operative atrial fibrillation)
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